Floatz logo

ANTI-CD22 ADC TRPH-222

Lymphoma, B-Cell

Triphase Research and Development III Corp.antibody_drug_conjugatePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

317 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

ANTI-CD22 ADC TRPH-222 is also rated in:

marginal zone lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
mantle cell lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →